2024
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.Peer-Reviewed Original ResearchNon-small cell lung cancerEnd of lifeMonth of deathImmunotherapy initiationCohort studyMAIN OUTCOMEStage IV non-small cell lung cancerCharlson-Deyo comorbidity indexHigh metastatic burdenInitiation of immunotherapyNational prescribing patternsRisk-adjusted patientsImmune checkpoint inhibitorsRetrospective cohort studyStage IV melanomaPercentage of patientsHigh-volume centersLocation of metastasesLow-volume centersOdds of deathCell lung cancerNational Clinical DatabaseLow-volume facilitiesDrug Administration approvalCheckpoint inhibitors
2018
Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma
Zhu R, Liu F, Grisotti G, Perez-Irizarry J, Salem RR, Cha CH, Johung KL, Boffa DJ, Zhang Y, Khan SA. Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma. Journal Of Gastrointestinal Oncology 2018, 9: 517-526. PMID: 29998017, PMCID: PMC6006033, DOI: 10.21037/jgo.2018.03.05.Peer-Reviewed Original ResearchPost-operative chemoradiationPeri-operative chemotherapyNode-positive gastric cancerAdjuvant therapyPositive gastric cancerGastric adenocarcinomaAdjuvant chemotherapyGastric cancerCurative-intent gastrectomyNational Cancer DatabasePercentage of patientsThird of patientsMean survival timeMultimodality careCurative gastrectomyOverall survivalSurgical resectionCancer outcomesCancer DatabasePoor survivalClinical impactLong-term effectsRadiation therapySurvival advantageSurvival time